Capricor Therapeutics Inc (NASDAQ: CAPR) on Monday, soared 3.31% from the previous trading day, before settling in for the closing price of $19.01. Within the past 52 weeks, CAPR’s price has moved between $2.90 and $23.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 339.72% over the last five years. The company achieved an average annual earnings per share of -44.41%. With a float of $40.01 million, this company’s outstanding shares have now reached $40.33 million.
The firm has a total of 102 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.71%, operating margin of -154.68%, and the pretax margin is -54151.28%.
Capricor Therapeutics Inc (CAPR) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Capricor Therapeutics Inc is 12.01%, while institutional ownership is 18.51%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.03 earnings per share (EPS) for the period topping the consensus outlook (set at -0.09) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -44.41% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
Capricor Therapeutics Inc (CAPR) is currently performing well based on its current performance indicators. A quick ratio of 4.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 38.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.06, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Analysing the last 5-days average volume posted by the [Capricor Therapeutics Inc, CAPR], we can find that recorded value of 1.18 million was better than the volume posted last year of 1.15 million. As of the previous 9 days, the stock’s Stochastic %D was 69.28%. Additionally, its Average True Range was 1.65.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 81.09%, which indicates a significant decrease from 83.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.06% in the past 14 days, which was lower than the 130.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.04, while its 200-day Moving Average is $8.33. Now, the first resistance to watch is $20.34. This is followed by the second major resistance level at $21.05. The third major resistance level sits at $21.95. If the price goes on to break the first support level at $18.73, it is likely to go to the next support level at $17.83. Should the price break the second support level, the third support level stands at $17.12.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
Market capitalization of the company is 891.62 million based on 45,470K outstanding shares. Right now, sales total 25,180 K and income totals -22,290 K. The company made 2,260 K in profit during its latest quarter, and -12,560 K in sales during its previous quarter.
